The Expressions of NF-κB, COX-2, Sp1, and c-Jun in Pancreatic Ductal Adenocarcinoma and Their Associations with Patient Survival.
Sp1
cyclooxygenase−2
c−Jun
nuclear factor kappa−B
pancreatic neoplasms
Journal
Pathophysiology : the official journal of the International Society for Pathophysiology
ISSN: 1873-149X
Titre abrégé: Pathophysiology
Pays: Switzerland
ID NLM: 9433813
Informations de publication
Date de publication:
25 Mar 2023
25 Mar 2023
Historique:
received:
15
12
2022
revised:
22
03
2023
accepted:
23
03
2023
medline:
24
4
2023
pubmed:
24
4
2023
entrez:
24
04
2023
Statut:
epublish
Résumé
Chronic inflammation is a crucial driver of carcinogenesis in pancreatic ductal adenocarcinoma (PDAC). Several studies have investigated the prognostic significance of cyclooxygenase-2 (COX-2) expression in PDAC patients, obtaining conflicting results. Nuclear factor kappa-B (NF-κB), specificity protein 1 (Sp1), and c-Jun are known as the transcription factors of the
Identifiants
pubmed: 37092523
pii: pathophysiology30020009
doi: 10.3390/pathophysiology30020009
pmc: PMC10123625
doi:
Types de publication
Journal Article
Langues
eng
Pagination
92-109Subventions
Organisme : University of Indonesia
ID : NKB-1589/UN2.RST/HKP.05.00/2020
Références
JAMA. 2021 Sep 7;326(9):851-862
pubmed: 34547082
Nature. 2003 Feb 6;421(6923):639-43
pubmed: 12571598
Cell Death Differ. 2006 May;13(5):759-72
pubmed: 16410803
World J Gastroenterol. 2010 Jun 21;16(23):2881-8
pubmed: 20556833
Oncol Rep. 1999 Sep-Oct;6(5):1117-22
pubmed: 10425312
Mol Cancer Ther. 2012 Oct;11(10):2127-37
pubmed: 22784710
Sci Rep. 2017 Mar 28;7(1):470
pubmed: 28352075
Br J Cancer. 2007 Aug 20;97(4):523-30
pubmed: 17622249
Mol Cancer Res. 2009 May;7(5):745-754
pubmed: 19435822
Gastroenterology. 2011 Oct;141(4):1473-85, 1485.e1-7
pubmed: 21763242
J Clin Pathol. 2006 Apr;59(4):382-6
pubmed: 16467169
Cancer Lett. 2018 May 1;421:127-134
pubmed: 29432846
World J Oncol. 2019 Feb;10(1):10-27
pubmed: 30834048
PLoS One. 2015 Feb 13;10(2):e0118004
pubmed: 25679523
Carcinogenesis. 2000 Feb;21(2):139-46
pubmed: 10657949
Onco Targets Ther. 2019 May 06;12:3387-3400
pubmed: 31118690
J Clin Invest. 2018 Jul 2;128(7):2732-2742
pubmed: 29733297
Prog Lipid Res. 2007 Mar;46(2):108-25
pubmed: 17316818
Curr Med Chem. 2012;19(22):3779-86
pubmed: 22725697
Cells. 2021 Jun 13;10(6):
pubmed: 34199169
Front Immunol. 2020 Nov 25;11:584626
pubmed: 33324403
Oncotarget. 2016 May 10;7(19):28207-17
pubmed: 27057636
Int J Cancer. 2009 Nov 1;125(9):2066-76
pubmed: 19588484
Br J Cancer. 2014 Aug 26;111(5):817-22
pubmed: 24755884
BMC Cancer. 2014 Jun 20;14:458
pubmed: 24950702
Clin Cancer Res. 2005 Apr 1;11(7):2518-25
pubmed: 15814628
Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1648-52
pubmed: 18628415
Biochem Pharmacol. 2004 Sep 15;68(6):1089-100
pubmed: 15313405
Oncol Lett. 2019 Jun;17(6):5361-5368
pubmed: 31186753
J Natl Compr Canc Netw. 2021 Apr 1;19(4):439-457
pubmed: 33845462
Am J Clin Oncol. 2008 Apr;31(2):157-62
pubmed: 18391600
Turk J Gastroenterol. 2021 Nov;32(11):956-970
pubmed: 34872897
Mol Cancer Res. 2010 Jun;8(6):821-32
pubmed: 20530583
Cancer Cell. 2007 Feb;11(2):119-32
pubmed: 17292824
Int J Cancer. 2017 Dec 15;141(12):2423-2429
pubmed: 28815606
Nat Rev Cancer. 2003 Nov;3(11):859-68
pubmed: 14668816
Prog Exp Tumor Res. 2003;37:52-71
pubmed: 12795048
Gastroenterol Res Pract. 2011;2011:214269
pubmed: 21760774
Oncology. 2013;85(2):86-94
pubmed: 23860225
Am J Clin Pathol. 2002 Aug;118(2):194-201
pubmed: 12162677
J Cell Physiol. 2019 May;234(5):5683-5699
pubmed: 30341914
Cancer Biol Ther. 2007 Oct;6(10):1569-75
pubmed: 18000398
Oncotarget. 2014 Nov 30;5(22):10969-75
pubmed: 25473891
Invest New Drugs. 2005 Dec;23(6):583-90
pubmed: 16034525
Oncotarget. 2016 Nov 29;7(48):78557-78565
pubmed: 27713167
World J Gastroenterol. 2014 Aug 21;20(31):10729-39
pubmed: 25152576
Oncogene. 2014 Jan 23;33(4):532-5
pubmed: 23334325
Tumour Biol. 2014 Oct;35(10):10301-7
pubmed: 25034525